Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study

被引:0
作者
Manzo, Antonio [1 ,2 ]
Cassione, Emanuele Bozzalla [1 ,2 ]
Montecucco, Carlomaurizio [1 ,2 ]
Sakellariou, Garifallia [1 ,3 ]
Xoxi, Blerina [1 ,2 ]
Luvaro, Terenzj [1 ,2 ]
Sammali, Ylenia [1 ,2 ]
De Stefano, Ludovico [1 ,2 ]
Alpini, Claudia [4 ]
Klersy, Catherine [5 ]
Bugatti, Serena [1 ,2 ]
机构
[1] Univ Pavia, Dept Internal Med & Therapeut, Rheumatol & Translat Immunol Res Labs LaRIT, Pavia, Italy
[2] Fdn IRCCS Policlin San Matteo, Div Rheumatol, Arthrit Res Clin ARC, Pavia, Italy
[3] Ist Clin Sci Maugeri SpA IRCCS Pavia, Pavia, Italy
[4] Fdn IRCCS Policlin San Matteo, Lab Biochem Clin Anal, Pavia, Italy
[5] Fdn IRCCS Policlin San Matteo, Biostat & Clin Trial Ctr, Pavia, Italy
来源
RMD OPEN | 2025年 / 11卷 / 01期
关键词
Rheumatoid Arthritis; Methotrexate; Anti-Citrullinated Protein Antibodies; Recurrence; Risk Factors; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; REMISSION CRITERIA; JOINT INFLAMMATION; CLASSIFICATION; DEFINITION; SCORE;
D O I
10.1136/rmdopen-2024-005079
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission on long-term drug-free (DF) outcomes. Methods RA patients, referring to the Pavia early arthritis clinic (EAC) between 2009 and 2021 and achieving remission after Disease Activity Score-driven methotrexate (MTX) monotherapy, were recruited. Eligible patients underwent DF follow-up at 3-month intervals over 5 years after MTX discontinuation. Pre-selected clinical, serological and ultrasound (US) exposure variables at MTX withdrawal were analysed using multivariable Cox regression to predict time-to-flare. Results Of 761 EAC patients with RA, 132 started DF follow-up (person-months: 3678). 62 experienced a flare after a median (range) of 9 (3-60) months, resulting in a progressive decline in flare-free survival throughout the observation period. Whole-cohort multivariate Cox regression identified anti-citrullinated protein antibody (ACPA) positivity (HR: 4.20, 95% CI 2.37 to 7.44) and hands' joints with grey scale (US-GS) alterations (GS>1; HR: 2.18, 95% CI 1.20 to 3.93) as independent predictors. ACPA-positive patients in Simplified Disease Activity Index (SDAI) remission displayed a flare-free survival estimate at 5 years of 6.4% (95% CI 1.2 to 35.7) versus 78.2% (95% CI 67.4 to 90.8) for ACPA-negative patients in SDAI remission without residual US-GS alteration in hands' joints (n=59); the latter group showing no evidence of radiographic progression and functional deterioration. Conclusions Long-term DF remission is attainable in a niche subset of ACPA-negative RA. Examining clinical and subclinical residual synovial abnormalities during remission allows for effective preemptive identification of this subset in real life.
引用
收藏
页数:13
相关论文
共 47 条
  • [1] Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
    Ahmad, Harris A.
    Baker, Joshua F.
    Conaghan, Philip G.
    Emery, Paul
    Huizinga, Thomas W. J.
    Elbez, Yedid
    Banerjee, Subhashis
    Ostergaard, Mikkel
    [J]. ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [2] Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms
    Ajeganova, S.
    van Steenbergen, H. W.
    van Nies, J. A. B.
    Burgers, L. E.
    Huizinga, T. W. J.
    van der Helm-van Mil, A. H. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 867 - 873
  • [3] Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study
    Akdemir, Gulsah
    Heimans, Lotte
    Bergstra, Sytske Anne
    Goekoop, Robbert J.
    van Oosterhout, Maikel
    van Groenendael, Johannes H. L. M.
    Peeters, Andre J.
    Steup-Beekman, Gerda M.
    Lard, Leroy R.
    de Sonnaville, Peter B. J.
    Grillet, Bernard A. M.
    Huizinga, Tom W. J.
    Allaart, Cornelia F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (01) : 111 - 118
  • [4] Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints
    Aletaha, Daniel
    Smolen, Josef S.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 3702 - 3711
  • [5] 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
    Aletaha, Daniel
    Neogi, Tuhina
    Silman, Alan J.
    Funovits, Julia
    Felson, David T.
    Bingham, Clifton O., III
    Birnbaum, Neal S.
    Burmester, Gerd R.
    Bykerk, Vivian P.
    Cohen, Marc D.
    Combe, Bernard
    Costenbader, Karen H.
    Dougados, Maxime
    Emery, Paul
    Ferraccioli, Gianfranco
    Hazes, Johanna M. W.
    Hobbs, Kathryn
    Huizinga, Tom W. J.
    Kavanaugh, Arthur
    Kay, Jonathan
    Kvien, Tore K.
    Laing, Timothy
    Mease, Philip
    Menard, Henri A.
    Moreland, Larry W.
    Naden, Raymond L.
    Pincus, Theodore
    Smolen, Josef S.
    Stanislawska-Biernat, Ewa
    Symmons, Deborah
    Tak, Paul P.
    Upchurch, Katherine S.
    Vencovsky, Jiri
    Wolfe, Frederick
    Hawker, Gillian
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (09): : 2569 - 2581
  • [6] Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis
    Alivernini, Stefano
    MacDonald, Lucy
    Elmesmari, Aziza
    Finlay, Samuel
    Tolusso, Barbara
    Gigante, Maria Rita
    Petricca, Luca
    Di Mario, Clara
    Bui, Laura
    Perniola, Simone
    Attar, Moustafa
    Gessi, Marco
    Fedele, Anna Laura
    Chilaka, Sabarinadh
    Somma, Domenico
    Sansom, Stephen N.
    Filer, Andrew
    McSharry, Charles
    Millar, Neal L.
    Kirschner, Kristina
    Nerviani, Alessandra
    Lewis, Myles J.
    Pitzalis, Costantino
    Clark, Andrew R.
    Ferraccioli, Gianfranco
    Udalova, Irina
    Buckley, Christopher D.
    Gremese, Elisa
    McInnes, Iain B.
    Otto, Thomas D.
    Kurowska-Stolarska, Mariola
    [J]. NATURE MEDICINE, 2020, 26 (08) : 1295 - +
  • [7] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [8] Guidelines for musculoskeletal ultrasound in rheumatology
    Backhaus, M
    Burmester, GR
    Gerber, T
    Grassi, W
    Machold, KP
    Swen, WA
    Wakefield, RJ
    Manger, B
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (07) : 641 - 649
  • [9] Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study
    Baker, Kenneth F.
    Skelton, Andrew J.
    Lendrem, Dennis W.
    Scadeng, Adam
    Thompson, Ben
    Pratt, Arthur G.
    Isaacs, John D.
    [J]. JOURNAL OF AUTOIMMUNITY, 2019, 105
  • [10] Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)
    Bingham, Clifton O., III
    Pohl, Christoph
    Woodworth, Tasia G.
    Hewlett, Sarah E.
    May, James E.
    Rahman, Mahboob U.
    Witter, James P.
    Furst, Daniel E.
    Strand, C. Vibeke
    Boers, Maarten
    Alten, Rieke E.
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2335 - 2341